Emerging Treatments in HIV

Feature Article

Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment

Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment

Once-daily regimens have been shown to improve adherence to treatment with no adverse effect on outcomes in patients with HIV.

Latest News

Tenofovir Alafenamide Plus Emtricitabine Safely and Effectively Treats HIV-1

Tenofovir Alafenamide Plus Emtricitabine Safely and Effectively Treats HIV-1

A head-to-head comparison was made between HIV-1 treatment regimens containing tenofovir alafenamide plus emtricitabine with those containing abacavir plus lamivudine.

FDA Approves Combination Treatment Symfi for HIV-1 Infection

FDA Approves Combination Treatment Symfi for HIV-1 Infection

Symfi contains the same triple combination ingredients found in the recently approved and launched Symfi Lo but with a 600mg dose of efavirenz vs 400mg seen in Symfi Lo.

Single Tablet HIV Regimen Noninferior to Abacavir-Containing Regimen

Single Tablet HIV Regimen Noninferior to Abacavir-Containing Regimen

A phase 3 study evaluating HIV patients who switched to treatment with Biktarvy found this combination therapy to be statistically noninferior to a regimen containing abacavir,

Intravenous Drug Approved for Multidrug-Resistant HIV Infection

Intravenous Drug Approved for Multidrug-Resistant HIV Infection

The FDA has approved Trogarzo for the treatment of adults with HIV whose infections are multidrug-resistant.

Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment

Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment

Once-daily regimens have been shown to improve adherence to treatment with no adverse effect on outcomes in patients with HIV.

EMERALD Trial: Week 48 Results Demonstrate Efficacy in Single-Tablet HIV Therapy

EMERALD Trial: Week 48 Results Demonstrate Efficacy in Single-Tablet HIV Therapy

Primary study end point was noninferiority of the single-tablet regimen vs control, related to virologic rebound, cumulative through week 48.

Bictegravir Co-Formulation Maintained High Levels of Virologic Suppression in HIV

Bictegravir Co-Formulation Maintained High Levels of Virologic Suppression in HIV

Phase 3 study assessed efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide from a multi-tablet regimen containing a boosted protease inhibitor regimen in virologically suppressed patients with HIV.

New Single-Tablet Treatment for HIV Infection Advantageous to Standard Therapy

New Single-Tablet Treatment for HIV Infection Advantageous to Standard Therapy

Virological response, efficacy, noninferiority, and tolerability were tested for bictegravir, emtricitabine, and tenofovir alafenamide vs dolutegravir, abacavir, and lamivudine.

FDA Grants Priority Review to Single Tablet HIV Regimen

FDA Grants Priority Review to Single Tablet HIV Regimen

The FDA has granted Priority Review to the New Drug Application for Gilead's investigational single-tablet regimen in the treatment of HIV-1 infection.

Amphotericin and Flucytosine Safe, Effective for HIV-Associated Cryptococcal Meningitis

Amphotericin and Flucytosine Safe, Effective for HIV-Associated Cryptococcal Meningitis

One-week amphotericin plus flucytosine was found to have comparable efficacy and safety profiles as the standard of care, 2-weeks amphotericin-based therapy, for treatment of HIV-associated cryptococcal meningitis in African patients.

Sign Up for Free e-newsletters